CytRx (CYTR) Collapses in After-hours Trading; Seagate Tech (STX) Boosts Revenue Outlook


CytRx Corp. (Nasdaq:CYTR) shares slumped more than 60% to touch a new 52-week low in the extended session Monday after the company said that results from a Phase 3 clinical trial showed that its rationally-engineered cytotoxic Aldoxorubicin did not perform better than investigator’s choice therapy for progression-free survival (PFS) – the study’s primary endpoint – in patients with soft tissue sarcoma

CYTR stock closed at $2.51, up $0.25 (or +11.06%), with a total volume of 6,094,958 shares traded during the day, representing a large increase in activity versus its average volume (3m) of 895,914 shares

CytRx, a biopharmaceutical research and development company specializing in oncology, has 68.32M Shares Outstanding. At close on Monday, the company had Market Capitalization (intraday) of $171.49M and CYTR stock one-year range was between $1.55 and $4.20 per share



Shares of Seagate Technology plc (Nasdaq:STX) climbed over 10% in after-hours trading Monday as the company boosted its revenue outlook on stronger-than-expected demand for its HDD product portfolio

The data storage solutions provider now expects to deliver fourth quarter fiscal 2016 revenue of about $2.65 billion in its financial results, well-above its previous guidance of approximately $2.3 billion and easily surpassing the Capital IQ Consensus Estimate of $2.34 billion in revenue for the period

STX stock finished at $24.09, up $0.08 (or +0.33%) and 5,375,891 of its shares changed hands on Monday

Seagate Technology, which designs, manufactures, and sells electronic data storage products, has 298.48M Shares Outstanding, Market Capitalization (intraday) of $7.19B and STX stock 52-week range is from $18.42 to $52.88 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at